These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35779846)

  • 41. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review.
    Fujiwara S; Miyauchi A; Hamaya E; Nicholls RJ; Weston A; Baidya S; Pinto L; Barron R; Takada J
    Arch Osteoporos; 2018 Mar; 13(1):34. PubMed ID: 29564555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
    Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
    Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
    J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
    Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
    Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-osteoporosis medication dispensing by clinical commissioning groups in England - an ecological study of variability in practice and of the effect of the Covid-19 pandemic.
    Janjua SS; Boardman HF; Sami A; Johansen A; Toh LS; Javaid KM
    Pharmacoepidemiol Drug Saf; 2023 Feb; 32(2):248-255. PubMed ID: 36125097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
    Morkos M; Mahrous P; Casagrande A; Go MT; Husni H; Hanna M; Goel M; Bedrose S; Li D; Baim S
    Endocr Pract; 2022 Oct; 28(10):1078-1085. PubMed ID: 35787466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
    Ishtiaq S; Fogelman I; Hampson G
    J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling.
    Winzenrieth R; Humbert L; Di Gregorio S; Bonel E; García M; Del Rio L
    Osteoporos Int; 2018 Oct; 29(10):2323-2333. PubMed ID: 29974136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures.
    Huang TW; Chuang PY; Lin SJ; Lee CY; Huang KC; Shih HN; Lee MS; Hsu RW; Shen WJ
    Medicine (Baltimore); 2016 May; 95(19):e3626. PubMed ID: 27175673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage.
    Cadarette SM; Carney G; Baek D; Gunraj N; Paterson JM; Dormuth CR
    Osteoporos Int; 2012 Apr; 23(4):1475-80. PubMed ID: 21901476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.
    Viggers R; Al-Mashhadi Z; Starup-Linde J; Vestergaard P
    Front Endocrinol (Lausanne); 2021; 12():826997. PubMed ID: 35154013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The pharmacological management of osteoporosis.
    Riek AE; Towler DA
    Mo Med; 2011; 108(2):118-23. PubMed ID: 21568234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.
    Elbers LPB; Raterman HG; Lems WF
    Drugs; 2021 Sep; 81(14):1645-1655. PubMed ID: 34524681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
    Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
    J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
    Ebina K; Hashimoto J; Kashii M; Hirao M; Miyama A; Nakaya H; Tsuji S; Takahi K; Tsuboi H; Okamura G; Etani Y; Takami K; Yoshikawa H
    Mod Rheumatol; 2021 Mar; 31(2):485-492. PubMed ID: 32412351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.